Berry Wealth Group LP Lowers Stake in AbbVie Inc. $ABBV

Berry Wealth Group LP cut its holdings in AbbVie Inc. (NYSE:ABBV) by 91.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,507 shares of the company’s stock after selling 15,297 shares during the quarter. AbbVie accounts for 1.1% of Berry Wealth Group LP’s investment portfolio, making the stock its 21st largest position. Berry Wealth Group LP’s holdings in AbbVie were worth $349,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Ellenbecker Investment Group raised its holdings in shares of AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after acquiring an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA increased its position in shares of AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after purchasing an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC lifted its holdings in AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after purchasing an additional 45 shares in the last quarter. Centennial Wealth Advisory LLC lifted its holdings in AbbVie by 2.2% in the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after purchasing an additional 45 shares in the last quarter. Finally, Willner & Heller LLC boosted its stake in AbbVie by 0.6% during the 3rd quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after purchasing an additional 46 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.25% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on ABBV. BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a report on Thursday, January 15th. Barclays initiated coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective on the stock. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Citigroup reduced their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Finally, Piper Sandler boosted their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Stock Down 1.7%

Shares of ABBV stock opened at $232.07 on Friday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm has a 50 day moving average of $224.72 and a two-hundred day moving average of $223.80. The stock has a market capitalization of $410.34 billion, a PE ratio of 98.33, a P/E/G ratio of 0.82 and a beta of 0.34.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is 293.22%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 AFFIRM results for risankizumab in moderately‑to‑severely active Crohn’s disease — higher clinical remission and endoscopic response vs. placebo, which could expand label/market for a high‑value asset and support longer‑term revenue growth. Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results
• Positive Sentiment: AbbVie advances venetoclax into a Phase 2 program for rare blood cancers in Japan — expands oncology pipeline and potential incremental revenue streams if studies read out positively. AbbVie Advances Venetoclax Into Rare Blood Cancers With New Phase 2 Study
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) highlights Medical Weight Loss data showing shifting patient demand — supports the aesthetics growth narrative and diversification beyond immunology. ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
• Positive Sentiment: Operationally constructive: AbbVie expansion reported to boost supply resilience for immunology medicines — lowers execution/supply risk for key franchises. AbbVie (NYSE:ABBV) Expansion Boosts Supply Resilience For Immunology Medicines
• Positive Sentiment: Third‑party bullish coverage and cash‑flow narratives emphasize AbbVie’s strong free cash flow and dividend profile — supportive for income investors and valuation stability. AbbVie: The Only Big Pharma Stock I’d Consider a Buy‑and‑Never‑Sell
• Neutral Sentiment: Corporate presentation/transcript from AbbVie at TD Cowen — may contain incremental detail on strategy and pipeline but no singular catalyst reported in the summary. AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Technical/market commentary notes the stock stabilizing near ~$233 while testing resistance levels — useful for short‑term traders but not a fundamental driver. AbbVie: Stabilizes Near $233 While Testing Resistance
• Neutral Sentiment: Market note reporting AbbVie’s share move relative to the broader market — descriptive of price action rather than a new driver. AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
• Negative Sentiment: Large senior notes offering (~$7.5–$8.0B) announced/completed — raises concerns about increased leverage and near‑term debt servicing; markets often view sizable debt raises as a near‑term negative for equity. AbbVie Completes $8 Billion Senior Notes Financing Offering AbbVie Announces $7.5 Billion Senior Notes Offering
• Negative Sentiment: AbbVie lost a bid to block Tennessee’s 340B law — regulatory/policy risk that could pressure pricing/reimbursements and is a negative for revenue in affected programs. AbbVie loses bid to block Tennessee 340B law

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.